Background: Opioid therapy for patients with chronic nonmalignant pain remains controversial, primarily because of safety concerns and the potential for abuse. The objective of this study was to examine trends in opioid utilization for nonmalignant pain among recipients of social assistance and to explore the relation between dose of analgesic and mortality.
1 Jan. 2003 and 31 Dec. 2008 . Second, we conducted an exploratory analysis of individuals in this group who had received at least one prescription for opioids in calendar year 2004, with the intent of characterizing the relation between opioid dose and the 2-year mortality rate. Ontario residents are eligible for drug coverage if they are unemployed or disabled, have high prescription drug costs in relation to their net household income, receive home care, reside in a long-term care facility or are 65 years of age or older. We restricted our analyses to individuals under 65 years of age who were eligible for drug coverage at the time of the study, because they represent a population of socio-economically disadvantaged individuals who are thought to be at especially high risk for misuse of opioids and associated harm. 12, 13 Data sources. We identified opioid treatment using the database of the Ontario Drug Benefit Program, which contains a detailed record of all prescription medications dispensed to Ontario residents eligible for coverage. We identified exclusionary cancer diagnoses using the Ontario Cancer Registry, a computerized database of information about all Ontario residents with a new diagnosis of cancer and those dying of cancer. We identified palliative care services, comorbidity and health resource utilization using hospital admissions data from the Canadian Institute for Health Information Discharge Abstract Database and physician billing data from the Ontario Health Insurance Plan (OHIP) database. We obtained demographic information, including date of death, from the Ontario Registered Persons Database, which contains a unique entry for each resident who has ever received insured health services. These databases were anonymously linked using 10-digit health card numbers, have been described extensively elsewhere [23] [24] [25] and are routinely used to investigate drug safety in Ontario. [26] [27] [28] This project was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre, Toronto.
Identification of patients.
We identified persons 15 to 64 years of age on 31 Dec. of each year who had received at least one prescription for an opioid analgesic during the same calendar year. We excluded individuals with any prior diagnosis of cancer and those receiving palliative care services in the 180 days preceding their first opioid prescription each year. A patient was deemed to have received palliative care if he or she had been admitted to hospital with a patient service code for palliative care or if a treating physician had billed OHIP for any of the following palliative care fee codes: A945, B998, C945, C882, C982, K023, W872, W882, W972 or W982.
T he use of opioid analgesics for the treatment of pain associated with cancer or end-of-life conditions is widely accepted. However, the appropriateness of these drugs for the treatment of chronic nonmalignant pain is the subject of considerable debate. [1] [2] [3] [4] [5] Systematic reviews have suggested that the safety and effectiveness of long-term opioid therapy remain unproven, [6] [7] [8] and recent studies have yielded conflicting results with respect to reduction of pain and improvement in quality of life and functional capacity for patients with chronic nonmalignant pain. [9] [10] [11] Furthermore, several studies have suggested a strong association between abuse of prescription opioids and younger age, poverty and unemployment. [12] [13] [14] [15] [16] Recognizing the potential for opioid abuse, addiction, diversion and related mortality, many jurisdictions have developed guidelines or implemented programs to promote more judicious use of these drugs. 21 However, only limited data are available regarding both the extent to which these thresholds are exceeded in clinical practice and the relative safety of such doses, particularly in vulnerable populations. The objective of this study was to examine temporal trends in opioid use and dosing and any association of these trends with opioid-related mortality among socioeconomically disadvantaged patients with chronic nonmalignant pain. We focused particularly on OxyContin (Purdue Pharma), a long-acting formulation of oxycodone, because evidence suggests that the prescribing of opioids and opioid-related mortality increased substantially in Ontario following the introduction of this formulation to the provincial formulary. 
Methods
Study designs. We performed two studies. First, we conducted a cross-sectional time series analysis examining annual prescription claims for opioid analgesics reimbursed by Ontario Public Drug Programs between and opioid-related deaths. 22 Although each patient was assigned to 1 of the 5 opioid groups annually on the basis of the hierarchy described above, all opioids dispensed for each patient contributed to the analyses. Therefore, a patient who switched treatment or received multiple opioid drugs in a given year was placed in only one exposure group (based on the hierarchy in Figure 1 ), but all of the person's opioid prescriptions were considered in the analyses. In a sensitivity analysis, we considered only the opioid or opioids specific to the treatment group (e.g., long-acting oxycodone) and disregarded concurrent therapy with other opioids.
Quantification of opioid use. For each individual who received at least one opioid prescription in a given calendar year, we calculated the mean daily dose dispensed (mg) of oral morphine, or equivalent, on the basis of the person's first 90 days of opioid therapy. If the supply of drug dispensed for a prescription in that interval extended beyond 90 days, we excluded the excess. The adjusted total amount of morphine equivalents dispensed over the 90 days was divided by 90 to obtain the mean daily dose for the period. Conservative morphine equivalence ratios were based on guidelines developed by the Canadian National Opioid Use Guideline Group (Table 1) 21 and are similar to those published elsewhere. 29, 30 In accordance with the guidelines, 1, 21 we categorized patients as having received a moderate dose of opioids if the mean daily dose was up to 200 mg of oral morphine (or equivalent), a high dose if the mean daily dose was between 201 and 400 mg of oral morphine (or equivalent) and a very high dose if the mean daily dose was more than 400 mg of oral morphine (or equivalent), based on the first 90 days of therapy in each year. We then calculated the percentage of patients in each dose category for each opioid therapy group in every year. Within each dose category of each opioid therapy group in 2008, we ascertained demographic information and health care utilization (i.e., number of hospital admissions and number of physician visits) in the past year. We also calculated the median daily amount (in milligrams of oral morphine or equivalent) of all opioids dispensed and of the opioid specific to the therapy group.
We examined prescriptions for codeine, morphine, oxycodone, hydromorphone, meperidine and transdermal fentanyl. We excluded prescriptions for parenteral and intranasal preparations of opioids and prescriptions for methadone, the latter because it is principally used for opioid addiction rather than chronic pain in Ontario.
Each individual was assigned to 1 of 5 mutually exclusive groups (Figure 1 ) on the basis of the characteristics of his or her opioid therapy over the course of each calendar year: long-acting oxycodone (regardless of other opioid therapy), transdermal fentanyl with no long-acting oxycodone, other long-acting opioids (with no long-acting oxycodone or fentanyl), immediate-release single-agent opioid therapy or combination products (which contain an immediate-release opioid and one of either acetaminophen or acetylsalicylic acid). This hierarchy was based on the clinical impression that recipients of longacting oxycodone and fentanyl receive higher doses than recipients of other long-acting opioids, as well as on the nature of the formulations (single v. multiple analgesics, immediate v. long-acting) and recent data suggesting an association between the addition of long-acting oxycodone to the formulary of Ontario's public drug plan by age and sex using direct standardization methods. We used Statistics Canada's 2006 Canadian population as the standard population for all standardized rates, and we approximated 95% confidence intervals (CIs) using a gamma interval based on the assumption that the rates were distributed as a weighted sum of independent Poisson random variables. 31 This method is considered more conservative than other similar methods. We used SAS version 9.2 statistical software (SAS Institute, Cary, NC) to perform all analyses.
Role of the sponsors. This study was supported by the Ontario Drug Policy Research Network, which is funded by a grant from the Ontario Ministry of Health and LongTerm Care (MOHLTC) Drug Innovation Fund and the Institute for Clinical Evaluative Sciences, a nonprofit research institute sponsored by the Ontario MOHLTC. The collection, analysis and interpretation of data, the results and conclusions reported in this paper, and the decision to submit the report for publication were the responsibility of the authors, independent from the funding sources.
Results
Over the 6-year study period, the annual prescribing rate for opioids rose by 16 A higher proportion of recipients of long-acting oxycodone were male (52%) than was the case for other opioid treatment groups (range 38% to 47%; Table 2 ).
Patterns of use of opioid analgesics. Over the study period, prescription rates in the long-acting oxycodone group more than doubled, from 331 per 1000 population in 2003 to 675 per 1000 population in 2008, whereas prescribing of combination analgesic therapy decreased by 14% (from 969 to 831 per 1000 population) and prescription rates in all other opioid groups remained stable (Figure 2) . By 2008, prescribing for long-acting oxycodone accounted for nearly one-fifth (n = 277 024 of 1 474 490; 18.8%) of all opioid prescriptions and more than half (n = 277 024 of 526 563; 52.6%) of all long-acting opioid prescriptions.
Opioid dose and risk of death. We conducted an exploratory cohort study to examine the risk of opioid-related death among all socio-economically disadvantaged patients aged 15 to 64 years who received a prescription for an opioid in 2004. We followed each patient for a maximum of 2 years from the date of the initial opioid prescription to the date of death or the end of follow-up (i.e., 2 years), as applicable. Using the records of the Office of the Chief Coroner of Ontario, we identified opioid-related deaths as deaths caused by a combination of drugs including at least one opioid, or death in which a toxicological analysis revealed opioid concentrations high enough to cause death. This method is described in more detail elsewhere. 22 We defined the period of analysis to exclude files from 2007 onward, to avoid cases in which the coroner's data were incomplete. For each opioid dose category (moderate, high and very high), we calculated age-and sex-standardized mortality rates over the subsequent 2 years, using the 2006 Ontario population as the standard population. Each patient was assigned to an opioid dose category according to the medication received during the first 90 days of therapy, as described above. We repeated the analysis for the risk of all-cause mortality, where deaths from any cause were identified from the Registered Persons Data Base. For comparison, we also calculated 2-year age-and sexstandardized all-cause mortality rates for the Ontario population aged 15 to 64 years on 1 Jan. 2004 who did not receive an opioid prescription in 2004.
Statistical analysis. We calculated basic descriptive statistics for the cross-sectional analyses: mean and standard deviation for normally distributed data and median and interquartile range for skewed data. In the exploratory cohort study, we standardized the mortality rates Table 2 (equivalence between oral morphine and transdermal fentanyl). The midpoint of the fentanyl ranges was used in our conversions.
high doses) are shown in Figure 4 . Although high doses of immediate-release opioids were uncommon, 20 Table 2 ). The median dose was unchanged in a sensitivity analysis that discounted all other opioids dispensed to these patients, which indicates that the high dose was driven primarily by prescriptions for long-acting oxycodone.
Between 2003 and 2008, the mean daily dose of opioid dispensed to each person remained relatively constant for all but two of the opioid therapy groups, the exceptions being patients with prescriptions for long-acting oxycodone and those with prescriptions for fentanyl. For patients receiving long-acting oxycodone, the mean daily dose rose by 27.4% (from 175 to 223 mg oral morphine equivalent) and for those receiving transdermal fentanyl, the mean daily dose rose by 14.2% (from 134 to 153 mg oral morphine equivalent) (Figure 3) . By 2008, the mean daily dose of opioids dispensed in the entire cohort was 42.4 mg oral morphine (or equivalent).
High-dose and very-high-dose opioid therapy. The trends in prescribing of daily opioid doses that exceeded current clinical guidelines (i.e., high and very oxycodone and, to a lesser extent, fentanyl. By 2008, roughly 1 of every 3 patients with a prescription for longacting oxycodone received a mean daily dose exceeding current clinical guidelines. 1, 21 This result suggests that clinicians may not fully appreciate the analgesic potency of oxycodone, which is roughly 1.5 to 2 times more potent than morphine and 10 to 20 times more potent than codeine. 32 Moreover, our exploratory analysis suggested that all-cause mortality rates may be associated with opioid dose, given that the all-cause mortality rate was more than 10 times higher among patients who received very high daily doses of opioids than among Ontarians without prescriptions for opioids. Although it might be argued that users of opioids are inherently different from non-users and are more likely to die regardless of their opioid use, we observed much greater differences in dose-related mortality for opioid-related deaths than for all-cause mortality. More specifically, relative to moderate doses of opioids, high and very high daily doses were associated with double the all-cause mortality rate but 5 to 6 times the opioid-related mortality rate. This differential in the relative change in opioid-related mortality with dose supports a direct association between opioid dose and opioid-related mortality, although was 4.00 (95% CI 3.95-4.04) per 1000 population (Table 3 ). In contrast, the rate was 20.05 (95% CI 19.38-20.73) per 1000 population among drug plan beneficiaries with a prescription for an opioid. When stratified by dose group, the age-and sex-standardized all-cause mortality rates were considerably higher among patients with high-dose prescriptions (42. for the treatment of short-and long-term pain, despite the fact that it is roughly 10 times more potent than codeine. 21 Dunn et al., 32 in a recent investigation of the relation between prescription of opioids and overdose, calculated a mean daily opioid dose of 13.3 mg (morphine equivalents), which is substantially lower than the mean daily dose that we observed (42.4 mg morphine equivalents) in the study reported here. Dunn et al. conducted their study in the state of Washington, where opioid guidelines were first published. 20 The study involved members of a unique Group Health Cooperative, among whom there were only 6 deaths. 32 Therefore, the differences between our findings and those of Dunn et al. may reflect differences in setting and study population. Although both studies described a dose-response relation between prescribing of opioids and risk of opioid-related death, our findings can more readily be generalized to socioeconomically disadvantaged individuals, a group at especially high risk of opioid abuse. 12, 13 Some limitations of our work merit emphasis. First, we were unable to determine the indications for or appropriateness of opioid therapy. However, the appropriateness of opioid therapy for chronic nonmalignant pain is itself controversial, and whether the prescriptions were appropriate would have little or no bearing on our observations regarding mortality. Second, although the classification of opioid-related deaths identified in data from the coroner's office was highly specific, some opioid-related deaths may have escaped detection. This type of error would lead to underestimation of opioid-related deaths in our analysis. Furthermore, our approach to defining opioid dosage (based on the first 90 days of opioid therapy in each year) and our use of conservative morphine equivalence ratios may have resulted in an underestimate of the number of people who received high or very high doses of opioid therapy for at least some part of each year. Third, the claims data that we used did not identify prescriptions for which the patient further research is needed to better understand this phenomenon.
We found that between 2003 and 2008, prescription rates for immediate-release opioid combination products decreased by 138 prescriptions per 1000 eligible people, while the corresponding rate for long-acting oxycodone prescriptions increased by more than twice this amount (344 prescriptions per 1000 eligible population). We speculate that this difference reflects, to some extent, a shift from the prescribing of codeine-acetaminophen combination products to long-acting oxycodone. 22 Longacting oxycodone has been aggressively marketed to primary care physicians and became a popular option paid out-of-pocket, nor did it identify drugs obtained through illicit means. Finally, although we adjusted for age and sex in our mortality analysis, we did not control for potential confounding variables such as comorbidity and past history of addiction, nor did our analysis reflect changes in opioid dose during follow-up. However, we believe it unlikely that the strong dose-response relation we observed could be explained entirely by residual confounding. In summary, in a large cohort of social assistance recipients aged 15 to 64 years, more than a quarter received at least one opioid prescription in 2008, and almost a third of those with a prescription for long-acting oxycodone received mean daily doses of opioids higher than recommended by current clinical guidelines. Almost 1% of patients with prescriptions for very high doses of opioids (> 400 mg morphine equivalent) died from opioid-related causes over a 2-year period.
Safety concerns regarding the use and misuse of opioid analgesics, particularly within younger and lowerincome populations, are becoming widely appreciated by the public and medical communities alike. 22, 34, 34 Our findings highlight the widespread prescription of very high doses of opioid analgesics, particularly among users of long-acting oxycodone, and indicate a relation between opioid dose and opioid-related mortality. These results suggest a need for greater awareness of opioid prescribing guidelines, along with a better appreciation of the potency and potential hazards of long-acting opioids in general and long-acting oxycodone in particular. Programs to educate physicians and pharmacists about opioid safety and appropriate dosing, as well as initiatives that allow real-time monitoring of medication use, may help in addressing these risks. 2, 19, [35] [36] [37] 
